SANOFI-AVENTIS (EPA:SAN) | WebDisclosure

Basculer en Français

10604	Companies
225013	Keywords
153734	Articles
119072	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 04/24/2026 at 20:30, 1 month 26 days ago

Communiqué de presse : Sanofi place 2,3 milliard d’euros d’emprunts obligataires
Sanofi réalise une émission obligataire de 2,3 milliards d’euros en 3 tranches, afin de soutenir ses besoins généraux. Les obligations ont été placées avec succès grâce à la collaboration de différents coordinateurs globaux

Émission Obligataire Sanofi Besoins Généraux Coordinateurs Globaux 2,3 Milliards
PRESS RELEASE

published on 04/24/2026 at 20:30, 1 month 26 days ago

Press Release: Sanofi successfully prices 2.3 billion of bond issue
Sanofi successfully prices €2.3 billion bond issue with notes across 3 tranches under Euro Medium Term Note programme. Net proceeds for general corporate purposes

Bond Issue Corporate Purposes Sanofi Euro Medium Term Note Global Coordinators
BRIEF

published on 04/24/2026 at 12:14, 1 month 26 days ago

Sanofi's Cenrifki Receives Positive CHMP Opinion for SPMS

Sanofi HERCULES Study CHMP Recommendation Cenrifki Approval SPMS Treatment
BRIEF

published on 04/24/2026 at 12:14, 1 month 26 days ago

Sanofi receives a favorable opinion for tolebrutinib in the treatment of multiple sclerosis

Multiple Sclerosis Approval Sanofi Tolebrutinib CMUH
BRIEF

published on 04/24/2026 at 12:14, 1 month 26 days ago

Sanofi obtient un avis favorable pour le tolebrutinib dans le traitement de la sclérose en plaques

Sclérose En Plaques Sanofi Approbation Tolebrutinib CMUH
BRIEF

published on 04/24/2026 at 12:14, 1 month 26 days ago

Cenrifki de Sanofi reçoit un avis favorable du CHMP pour SPMS

Sanofi Étude HERCULES Approbation De Cenrifki Traitement De La SEP Progressive Secondaire Recommandation Du CHMP
PRESS RELEASE

published on 04/24/2026 at 12:09, 1 month 26 days ago

Press Release: Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses
CHMP recommends EU approval for Sanofi's Cenrifki (tolebrutinib) to treat secondary progressive multiple sclerosis without relapses. Positive opinion based on HERCULES phase 3 study

Multiple Sclerosis Sanofi CHMP Tolebrutinib Cenrifki
PRESS RELEASE

published on 04/24/2026 at 12:09, 1 month 26 days ago

Communiqué de presse : Cenrifki de Sanofi (tolebrutinib) recommandé par le Comité des médicaments à usage humain (CMUH) pour être approuvé par l’UE pour le traitement de la sclérose en plaques secondairement progressive sans poussées
Sanofi's Cenrifki (tolebrutinib) recommended for EU approval by CHMP for secondary progressive multiple sclerosis without relapses, based on positive results from HERCULES phase 3 study

Multiple Sclerosis Sanofi CHMP EU Approval Cenrifki
BRIEF

published on 04/22/2026 at 23:35, 1 month 28 days ago

Sanofi et Regeneron obtiennent l'approbation de la FDA pour Dupixent chez les jeunes enfants

Approbation De La FDA Sanofi Dupixent Regeneron Médecine Pédiatrique
BRIEF

published on 04/22/2026 at 23:35, 1 month 28 days ago

Sanofi and Regeneron Win FDA Approval for Dupixent in Young Children

FDA Approval Sanofi Dupixent Regeneron Pediatric Medicine

Accesswire

Published on 06/20/2026 at 01:00, 1 day 7 hours ago

Onco-Innovations Announces Non-Brokered LIFE Offering
Published on 06/20/2026 at 00:00, 1 day 8 hours ago

Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development
Published on 06/19/2026 at 04:30, 2 days 4 hours ago

Uraniumx Discovery Corp. Announces Acquisition of Common Shares of Gold'n Futures Mineral Corp
Published on 06/19/2026 at 01:20, 2 days 7 hours ago

American Hotel Income Properties REIT LP Reports Voting Results of Annual and Special Meeting
Published on 06/19/2026 at 01:07, 2 days 7 hours ago

Usha Resources Announces Share Issuance in Payment of Debenture Interest, Adopts Semi-Annual Reporting

View all ACCESSWIRE

EQS Group

Published on 06/20/2026 at 21:25, 11 hours 12 minutes ago

VIVATECH 2026 CELEBRATES ITS 10TH ANNIVERSARY WITH A RECORD EDITION SURPASSING 200,000 VISITORS
Published on 06/20/2026 at 06:00, 1 day 2 hours ago

Successful debut of International Symposium on Emergency Response and Aeromedical Services in Hong Kong
Published on 06/19/2026 at 20:17, 1 day 12 hours ago

2CRSi SA: 2CRSi Responds Point-by-Point to the Grizzly Research Report and Reaffirms the Reality of Its Business Operations
Published on 06/19/2026 at 20:17, 1 day 12 hours ago

2CRSi SA: 2CRSi répond point par point au rapport de Grizzly Research et réaffirme la réalité de son activité
Published on 06/19/2026 at 19:01, 1 day 13 hours ago

Fuller, Smith & Turner PLC: Publication of the Annual Report and Accounts for the 52 weeks ending 28 March 2026 and Notice of 2026 Annual General Meeting

Les Echos

Published on 06/19/2026 at 19:33, 1 day 13 hours ago

Déclaration hebdomadaire d'opérations effectuées du 15 au 19 juin 2026
Published on 06/19/2026 at 19:33, 1 day 13 hours ago

Disclosure of transactions in own shares from June 15 to June 19, 2026
Published on 06/19/2026 at 19:23, 1 day 13 hours ago

Imerys-06-2026-communique-capital-droits-de-vote-au-31-mai-2026
Published on 06/19/2026 at 19:23, 1 day 13 hours ago

Imerys-06-2026-information-share-capital-and-voting-rights-as-of-31-May-2026
Published on 06/19/2026 at 19:05, 1 day 13 hours ago

CP - Changement de gouvernance

View all LES ECHOS COMFI WIRE